Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 18/20 | 0.60 |
| ▸ | CTSK | P43235 | 16/20 | 0.60 |
| ▸ | CTSL | P07711 | 2/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27939620 | 0.87 | CTSS (0.53) | CTSSCTSKCTSLCTSBTDP1 | |
| SCHEMBL4689061 | 0.83 | TDP1 (0.50) | CTSSCTSKCTSLCTSBTDP1 | |
| SCHEMBL1304101 | 0.82 | TDP1 (0.53) | CTSSCTSKCTSLCTSBTDP1 | |
| SCHEMBL1600167 | 0.80 | TDP1 (0.50) | CTSSCTSKCTSLCTSBTDP1 | |
| SCHEMBL211262 | 0.80 | TDP1 (0.50) | CTSSCTSKCTSLCTSBTDP1 | |
| SCHEMBL9201935 | 0.80 | MAOA (0.56) | CTSSCTSKCTSLCTSBTDP1 | |
| SCHEMBL1519817 | 0.79 | MEN1 (0.60) | CTSSCTSKCTSLCTSBTDP1 | |
| SCHEMBL6447493 | 0.79 | CTSS (0.57) | CTSSCTSKCTSLCTSB | |
| SCHEMBL16913 | 0.78 | TDP1 (0.48) | CTSSCTSKCTSLCTSBTDP1 | |
| SCHEMBL5558068 | 0.77 | TDP1 (0.62) | CTSSCTSKCTSLCTSBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| CN-115340591-B | Intracellular self-assembled protein degradation agent based on VH032 and preparation method and application thereof | 西安交通大学 | 2025-04-25 | — | — | CN | disclosed |
| CN-115286687-B | Intracellular self-assembly degradation agent based on bio-orthogonal reaction and preparation method and application thereof | 西安交通大学 | 2025-04-25 | — | — | CN | disclosed |
| EP-4490152-A1 | ACTIVATORS OF EFFECTOR T CELLS | Orum Therapeutics Inc. (KR) | 2025-01-15 | — | — | EP | disclosed |
| EP-4463458-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | Deutsches Krebsforschungszentrum (DE) | 2024-11-20 | — | — | EP | disclosed |
| CN-118084867-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084868-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084866-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084870-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11857636-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2024-01-02 | — | — | US | disclosed |
| WO-2002044145-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | WO | disclosed |
| EP-0669336-B1 | NOVEL CEPHEM DERIVATIVES | MEIJI SEIKA CO (JP) | 2000-05-17 | — | — | EP | disclosed |
| US-5663162-A | BACTERICIDES AND ANTIBIOTICS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-09-02 | — | — | US | disclosed |
| EP-0669336-A1 | NOVEL CEPHEM DERIVATIVE | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-08-30 | — | — | EP | disclosed |
| EP-0420934-B1 | BIFUNCTIONAL COUPLING AGENTS AND RADIONUCLIDE LABELED COMPOSITIONS PREPARED THEREFROM | CENTOCOR INC (US) | 1994-09-21 | — | — | EP | disclosed |
| US-5218128-A | Medical disgnosis | CENTOCOR, INC. (US) | 1993-06-08 | — | — | US | disclosed |
| EP-0420934-A1 | BIFUNCTIONAL COUPLING AGENTS AND RADIONUCLIDE LABELED COMPOSITIONS PREPARED THEREFROM. | CENTOCOR INC (US) | 1991-04-10 | — | — | EP | disclosed |
| WO-1989012625-A1 | BIFUNCTIONAL COUPLING AGENTS AND RADIONUCLIDE LABELED COMPOSITIONS PREPARED THEREFROM | CENTOCOR, INC. (US) | 1989-12-28 | — | — | WO | disclosed |
| US-4829053-A | Amino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-05-09 | — | — | US | disclosed |
| EP-0262318-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1988-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | CTSS 874/4885CTSK 715/4885CTSL 718/4885 |
| US-11857636-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | CTSS 201/4885CTSK 208/4885CTSL 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.